EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2	"20060128635"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/04/01 14:01
L2	2	"20060166899"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/04/01 14:01
L3	2	2 and cycloalkyl	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/04/01 15:09
L4	3	"20040063646"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/04/01 14:39
L5	2	"6683056".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/04/01 15:18
L6	708	536/17.2.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/04/01 15:18
L7	205	536/17.3.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/04/01 15:18

EAST Search History

L8	724	536/18.1.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/04/01 15:18
L9	1495	514/25.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/04/01 15:18
L10	1174	514/27.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/04/01 15:18

C:\Program Files\Stnexp\Queries\10523820b.str





chain nodes :
12 13 15 16 19 20 23 24 26 29 30 31 32 33 34 36 37 38 39 40 41 43 44 45 46 47 48
ring nodes :
1 2 3 4 5 6 7 8 9 10 11
ring/chain nodes :
21 25 35 42 49 50
chain bonds :
2-12 5-13 8-16 9-12 10-15 19-20 19-21 23-24 23-25 23-26 29-31 30-32 31-33 32-40 33-34 33-35 36-38
37-39 38-43 39-44 40-41 40-42 43-45 43-46 43-49 44-47 44-48 44-50
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-13 7-8 7-11 8-9 8-16 9-10 10-11 10-15 19-20 19-21 23-24 23-25 23-26 29-31
30-32 31-33 32-40 33-34 33-35 36-38 37-39 38-43 39-44 40-41 40-42 43-45 43-46 43-49 44-47 44-48 44-50
exact bonds :
2-12 9-12

G1:C,S

G2:O,Cb,Ak

G3:[*1],[*2],[*3],[*4],[*5],[*6]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:CLASS 13:CLASS 15:CLASS
16:CLASS 19:CLASS 20:CLASS 21:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS
33:CLASS

```
     (FILE 'HOME' ENTERED AT 13:42:38 ON 01 APR 2007)

     FILE 'REGISTRY' ENTERED AT 13:43:00 ON 01 APR 2007
L1             STRUCTURE UPLOADED
L2               5 S L1 SSS SAM
L3              72 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 13:43:48 ON 01 APR 2007
L4              12 S L3
```

34:CLASS35:CLASS36:CLASS37:CLASS38:CLASS39:CLASS40:CLASS41:CLASS42:CLASS43:CLASS44:CLASS
45:CLASS46:CLASS47:CLASS48:CLASS49:CLASS50:CLASS

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1600txm

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 4	DEC 18	CA/CAplus patent kind codes updated
NEWS 5	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS 6	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS 7	DEC 27	CA/CAplus enhanced with more pre-1907 records
NEWS 8	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 9	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 10	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 11	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 12	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 13	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 14	JAN 29	PHAR reloaded with new search and display fields
NEWS 15	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 16	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 17	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS 18	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS 19	FEB 26	MEDLINE reloaded with enhancements
NEWS 20	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS 21	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS 22	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 23	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS 24	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 25	MAR 16	CASREACT coverage extended
NEWS 26	MAR 20	MARPAT now updated daily
NEWS 27	MAR 22	LWPI reloaded
NEWS 28	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS 29	MAR 30	INPADOCDB will replace INPADOC on STN

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:42:38 ON 01 APR 2007

=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION

```
FULL ESTIMATED COST                                    0.21       0.21

FILE 'REGISTRY' ENTERED AT 13:43:00 ON 01 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   30 MAR 2007  HIGHEST RN 928818-37-5
DICTIONARY FILE UPDATES:  30 MAR 2007  HIGHEST RN 928818-37-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10523820b.str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 13:43:32 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      235 TO ITERATE

100.0% PROCESSED      235 ITERATIONS                              5 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         3781 TO     5619
PROJECTED ANSWERS:               5 TO      234

L2            5 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 13:43:43 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     4964 TO ITERATE

100.0% PROCESSED     4964 ITERATIONS                            72 ANSWERS
SEARCH TIME: 00.00.01

L3           72 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             172.10     172.31

FILE 'CAPLUS' ENTERED AT 13:43:48 ON 01 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 1 Apr 2007 VOL 146 ISS 15
FILE LAST UPDATED: 30 Mar 2007 (20070330/ED)

=> s l3'
L4 12 L3

=> d bib abs hitstr 1-12 l4

L4 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1346218 CAPLUS
DN 144:88321
TI Preparation of triazinyl and other carboxamides as inhibitors of histone deacetylase
IN Delorme, Daniel; Woo, Soon Hyung; Vaisburg, Arkadii; Moradei, Oscar; Leit, Silvana; Raeppel, Stephane; Frechette, Sylvie; Bouchain, Giliane
PA Methylgene, Inc., Can.
SO U.S. Pat. Appl. Publ., 324 pp., Cont.-in-part of U.S. Ser. No. 358,556.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005288282	A1	20051229	US 2005-91025	20050325
	US 2004106599	A1	20040603	US 2002-242304	20020912
	US 2004142953	A1	20040722	US 2003-358556	20030204
	US 6897220	B2	20050524		
	JP 2005255683	A	20050922	JP 2005-80310	20050318
	AU 2006252047	A1	20070111	AU 2006-252047	20061214
PRAI	US 2001-322402P	P	20010914		
	US 2002-391728P	P	20020626		
	US 2002-242304	A2	20020912		
	US 2003-358556	A2	20030204		
	AU 2002-327627	A3	20020912		
	JP 2003-528544	A3	20020912		

OS MARPAT 144:88321
GI



I



II

McIntosh

AB The invention provides compds. and methods for inhibiting histone deacetylase enzymic activity. Such compds. include carboxamides I [Cy2 = (un)substituted cycloalkyl, aryl, heteroaryl, heterocyclyl (each of which is optionally fused to one or two aryl or heteroaryl rings, or to one or two (un)saturated cycloalkyl or heterocyclic rings); X1 = a bond, M1L2M1, L2M2L2 (wherein L2 = a bond, alkylene, alkenylene, alkynylene; M1 = O, S, SO, NHCO, etc.; M2 = M1, heteroarylene, heterocyclylene); Ar2 = (un)substituted (hetero)arylene; R5, R6 = H, alkyl, aryl, aralkyl; q = 0-1; Ay2 = (un)substituted 5-6 membered cycloalkkyl, heterocyclyl or heteroaryl substituted with an amino or hydroxy moiety; with provisos] which were prepared and claimed. E.g., a multi-step synthesis of II, starting from Me 4-(aminomethyl)benzoate.HCl, was given. The invention also provides compns. and methods for treating cell proliferative diseases and conditions. Antineoplastic effects of some I are illustrated for colorectal, pulmonary and pancreatic neoplasms; also the combined antineoplastic effect of histone deacetylase inhibitors and histone deacetylase antisense oligonucleotides on tumor cells in vivo was demonstrated. Although the methods of preparation are not claimed, hundreds of example prepns. are included.

IT 503040-37-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of triazinyl and other carboxamides as inhibitors of histone deacetylase for treating cell proliferative disorders)

RN 503040-37-7 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1328798 CAPLUS
DN 144:51831
TI Synthesis of fluoro-glycoside derivs. of pyrazoles for use in treatment of diabetes or for lowering blood sugar levels
IN Brummerhop, Harm; Frick, Wendelin; Glombik, Heiner; Plettenburg, Oliver; Bickel, Martin; Heuer, Hubert; Theis, Stefan
PA Aventis Pharma Deutschland G.m.b.H., Germany
SO PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005121161	A1	20051222	WO 2005-EP5959	20050603

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,

LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

DE	102004028241	A1	20060105	DE 2004-102004028241	20040611
AU	2005252329	A1	20051222	AU 2005-252329	20050603
CA	2570042	A1	20051222	CA 2005-2570042	20050603
EP	1758914	A1	20070307	EP 2005-746637	20050603

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,
HR, LV, MK, YU

PRAI DE 2004-102004028241 A 20040611
WO 2005-EP5959 W 20050603
OS MARPAT 144:51831
GI



I

AB The invention relates to substituted fluoro-glycoside derivs. of pyrazoles, e.g. (I), and their physiol. compatible salts, which inhibit Na+-dependent glucose transporter 1 (SGLT-1) and to a method for their production Thus, 1-bromo-4-deoxy-4-fluoro-2,3,6-tri-O-benzoyl-α-D-glucopyranose was prepared from Me 2,3,6-tri-O-benzoyl α-D-galactopyranose in 3 steps, and reacted with 4-(4-bromo-benzyl)-5-isopropylpyraz-3-ol, prepared from Me 4-methyl-3-oxopentanoate in 2 steps, to give the β-linked pyrazole intermediate (II). II was then reacted with 3-butenoic acid, followed by a condensation reaction with n-butylamine and deprotection of the sugar oxygens to give I. In in vitro tests using CHO-TRex-hSGLT1 cell line (derivation given), measuring the concentration at which uptake of Me α-D-glucopyranoside was reduced by 50%, I had IC50 value of 0.043 μM.

IT 871484-43-4P 871484-44-5P 871484-45-6P
871484-46-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of fluoro-glycoside derivs. of pyrazoles for use in treatment of diabetes or for lowering blood sugar levels)

RN 871484-43-4 CAPLUS

CN Benzamide, N-(3-amino-3-oxopropyl)-4-[[3-[(4-deoxy-4-fluoro-β-D-glucopyranosyl)oxy]-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 871484-44-5 CAPLUS
CN Benzamide, N-(2-amino-2-oxoethyl)-4-[[3-[(4-deoxy-4-fluoro-β-D-glucopyranosyl)oxy]-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 871484-45-6 CAPLUS
CN Benzamide, N-(3-amino-3-oxopropyl)-4-[[3-[(4-deoxy-4-fluoro-β-D-glucopyranosyl)oxy]-5-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 871484-46-7 CAPLUS
CN Benzamide, N-(2-amino-2-oxoethyl)-4-[[3-[(4-deoxy-4-fluoro-β-D-glucopyranosyl)oxy]-5-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 871484-11-6P 871484-12-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of fluoro-glycoside derivs. of pyrazoles for use in treatment of diabetes or for lowering blood sugar levels)

RN 871484-11-6 CAPLUS
CN Benzamide, N-(3-amino-3-oxopropyl)-4-[[1-(2-cyanoethyl)-5-hydroxy-3-(1-methylethyl)-1H-pyrazol-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 871484-12-7 CAPLUS
CN Benzamide, N-(3-amino-3-oxopropyl)-4-[[1-(2-cyanoethyl)-3-(1-methylethyl)-5-[(2,3,6-tri-O-benzoyl-4-deoxy-4-fluoro-β-D-glucopyranosyl)oxy]-1H-pyrazol-4-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:589250 CAPLUS
DN 141:140470
TI Preparation of aminophenylbenzamides as inhibitors of histone deacetylase
IN Delorme, Daniel; Zhou, Zhihong
PA Methylgene, Inc., Can.
SO U.S. Pat. Appl. Publ., 318 pp., Cont.-in-part of U.S. Ser. No. 242,304.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004142953	A1	20040722	US 2003-358556	20030204
	US 6897220	B2	20050524		
	US 2004106599	A1	20040603	US 2002-242304	20020912
	AU 2004210016	A1	20040819	AU 2004-210016	20040204
	CA 2515338	A1	20040819	CA 2004-2515338	20040204
	WO 2004069823	A1	20040819	WO 2004-CA139	20040204
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1590340	A1	20051102	EP 2004-707852	20040204
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1723207	A	20060118	CN 2004-80001769	20040204
	BR 2004007195	A	20060214	BR 2004-7195	20040204
	JP 2006514998	T	20060518	JP 2005-518241	20040204
	US 2006058298	A1	20060316	US 2005-81095	20050315
	JP 2005255683	A	20050922	JP 2005-80310	20050318
	US 2005288282	A1	20051229	US 2005-91025	20050325
	IN 2005KN01604	A	20061103	IN 2005-KN1604	20050810
	AU 2006252047	A1	20070111	AU 2006-252047	20061214
PRAI	US 2001-322402P	P	20010914		
	US 2002-391728P	P	20020626		
	US 2002-242304	A2	20020912		
	AU 2002-327627	A3	20020912		
	JP 2003-528544	A3	20020912		
	US 2003-358556	A	20030204		
	WO 2004-CA139	W	20040204		

OS MARPAT 141:140470
GI



AB Title compds. e.g. (I; Y, Z = N, CH; W = Q1, Q2, Q3, etc.), were prepared Thus, 4-[[(4-Amino-6-(2-indanylamino)-[1,3,5]triazin-2-yl)amino]methyl]benzoic acid (preparation given) in DMF was stirred with Et3N, BOP, and 1,2-phenylenediamine to give 63% 4-[[(4-Amino-6-(2-indanylamino)-[1,3,5]triazin-2-yl)amino]methyl]-N-(2-aminophenyl)benzamide. The latter inhibited human histone deacetylase HDAC-1 with IC50 = 0.4 μM.

IT 503040-37-7P, N-(2-Aminophenyl)-4-[(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)methyl]benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aminophenylbenzamides as inhibitors of histone deacetylase for treating cell proliferative disorders)

RN 503040-37-7 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-[(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:512993 CAPLUS
DN 141:76809
TI Anti-inflammatory coatings for implantable medical devices containing a TACE inhibitor
IN Dodd, John H.
PA USA
SO U.S. Pat. Appl. Publ., 14 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004120977	A1	20040624	US 2003-732570	20031210
	WO 2004060212	A1	20040722	WO 2003-US39312	20031210

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	AU 2003297849	A1	20040729	AU 2003-297849	20031210
PRAI	US 2002-434007P	P	20021217		
	US 2003-482273P	P	20030625		
	WO 2003-US39312	W	20031210		

OS MARPAT 141:76809

AB The present invention relates to implantable surgical medical devices having coatings comprising one or more compds. that inhibit TNF-α converting enzyme (TACE), more particularly, stents having coatings comprising TACE inhibitors. A TACE inhibitor is effective in reducing restenosis.

IT 461664-87-9
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-inflammatory coatings for implantable medical devices containing TACE inhibitor)

RN 461664-87-9 CAPLUS

CN 1-Oxaspiro[4.4]nonane-7-carboxamide, 8-[[4-[(3,5-dimethyl-1H-pyrazol-4-yl)methyl]benzoyl]amino]-N-hydroxy-, (5R,7S,8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:311011 CAPLUS

DN 140:321649

TI Preparation of pyrazolyl glycoside derivatives as inhibitors of 1,5-anhydroglucitol/fructose/mannose transporters

IN Fujikura, Hideki; Kikuchi, Norihiko; Tazawa, Shigeki; Yamato, Tokuhisa; Isaji, Masayuki

PA Kissei Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 159 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004031203	A1	20040415	WO 2003-JP12477	20030930

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	CA 2500873	A1	20040415	CA 2003-2500873	20030930
	AU 2003272903	A1	20040423	AU 2003-272903	20030930
	EP 1550668	A1	20050706	EP 2003-753967	20030930
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2006128635	A1	20060615	US 2005-529895	20050919
PRAI	JP 2002-293090	A	20021004		
	JP 2002-330694	A	20021114		
	JP 2002-378959	A	20021227		
	WO 2003-JP12477	W	20030930		

OS MARPAT 140:321649

GI

10/529,895

this has aryl groups, my app has alkyl/cycloalkyl groups - not the same - in the Q/T positions



I II

AB The title compds. [I; R = each (un)substituted C3-8 cycloalkyl, C6-10 aryl, C2-9 heterocycloalkyl, or C1-9 heteroaryl; R1 = H, each (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, C6-10 aryl, C2-9 heterocycloalkyl, or C1-9 heteroaryl; one of Q0 and T0 = α- or β-D-glucopyranosyloxy or -mannopyranosyloxy or β-D-deoxyglucopyranosyloxy- and the other = (CH2)nAr; wherein Ar = each (un)substituted C6-10 aryl or C1-9 heteroaryl; n = an integer of 0-2] or pharmacol. acceptable salts or prodrugs thereof are prepared Also disclosed are medicinal composition containing the compound I, medicinal use thereof, and intermediates in producing the same. These compds. exerts an excellent effect of inhibiting human 1,5-anhydroglucitol/fructose/mannose transporters and inhibit reabsorption or cellular uptake of glucose, fructose, and mannose in kidney or absorption of these saccharide small intestine and inhibit the increase in blood sugar. Therefore, they are useful as preventives, progress inhibitors or remedies for a disease caused by the over intake of at least one saccharide selected from among glucose, fructose, and mannose or a disease caused by hyperglycemia (diabetic complication, diabetes, or diabetic nephropathy). Thus, glycosidation of 1-isopropyl-5-(4-methoxyphenyl)-4-[(4-methoxyphenyl)methyl]-1,2-dihydro-3H-pyrazol-3-one by acetobromo-α-D-glucose in the presence of benzyltributylammonium bromide in a mixture of CH2Cl2 and 5 N aqueous NaOH at room temperature for 1.5 h followed by treatment of the product with NaOMe in MeOH gave 3-(β-D-glucopyranosyloxy)-1-isopropyl-5-(4-methoxyphenyl)-4-[(4-methoxyphenyl)methyl]-1H-pyrazole (II). II in vitro inhibited the uptake of [14C]methyl α-D-glucopyranoside in COS-7 cells transfected with human SMINT/PME18S-FL expression plasmid with IC50 of 92 nM.

IT 678994-69-9P 678994-70-2P 678994-71-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolyl glycoside derivs. as inhibitors of 1,5-anhydroglucitol/fructose/mannose transporters and preventives, progress inhibitors or remedies for diabetic complication, diabetes, or diabetic nephropathy)

RN 678994-69-9 CAPLUS

CN Acetamide, 2-[4-[[3-(β-D-glucopyranosyloxy)-5-(4-methoxyphenyl)-1-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methoxyphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-70-2 CAPLUS
CN Acetamide, 2-[4-[[5-(4-ethylphenyl)-3-(β-D-glucopyranosyloxy)-1-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methoxyphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-71-3 CAPLUS
CN Acetamide, 2-[4-[[3-(β-D-glucopyranosyloxy)-1-(1-methylethyl)-5-[4-(1-methylethyl)phenyl]-1H-pyrazol-4-yl]methyl]-3-methoxyphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 678995-16-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolyl glycoside derivs. as inhibitors of 1,5-anhydroglucitol/fructose/mannose transporters and preventives,

progress inhibitors or remedies for diabetic complication, diabetes, or diabetic nephropathy)

RN 678995-16-9 CAPLUS

CN Acetamide, 2-[3-methoxy-4-[[5-(4-methoxyphenyl)-1-(1-methylethyl)-3-[(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)oxy]-1H-pyrazol-4-yl]methyl]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:143172 CAPLUS

DN 140:199632

TI Preparation of pyrazolyl glucopyranoside and galactopyranoside derivatives inhibitors of human sodium-glucose cotransporter 1 (SGLT1), medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof

IN Teranishi, Hirotaka; Fushimi, Nobuhiko; Yonekubo, Shigeru; Shimizu, Kazuo; Shibazaki, Toshihide; Isaji, Masayuki

PA Kissei Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 215 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

my app

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004014932	A1	20040219	WO 2003-JP10048	20030807
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2494179	A1	20040219	CA 2003-2494179	20030807
	AU 2003254847	A1	20040225	AU 2003-254847	20030807
	EP 1544208	A1	20050622	EP 2003-784564	20030807
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003013290	A	20050705	BR 2003-13290	20030807
	CN 1688596	A	20051026	CN 2003-823929	20030807
	NZ 538117	A	20070126	NZ 2003-538117	20030807
	US 2006166899	A1	20060727	US 2005-523820	20050204
	NO 2005001209	A	20050415	NO 2005-1209	20050308
PRAI	JP 2002-232074	A	20020808		
	JP 2002-321729	A	20021105		
	WO 2003-JP10048	W	20030807		

OS MARPAT 140:199632

GI



I

AB Pyrazoles derivs. represented by the general formula (I) [R1 = H, C1-5 alkyl, C2-5 alkenyl, hydroxy-C2-5 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6 alkyl (un)substituted aryl or aryl-C1-6 alkyl; one of Q and T = Q1, Q2 and the other = C1-5 alkyl, halo-C1-6 alkyl, C1-6 alkoxy-C1-6 alkyl, C3-7 cycloalkyl; R2 = H,halo, OH, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, halo-C1-6 alkyl, halo-C1-6 alkoxy, C1-6 alkoxy-C1-6 alkoxy, C3-7 cycloalkyl-C2-6 alkoxy, etc.; X = a single bond, O, S; Y = a single bond, C1-6 alkylene, C2-6 alkenylene; Z = CO, SO2; R4, R5 = H, (un)substituted C1-6 alkyl; or NR4R5 together forms an (un)substituted C2-6 cyclic amino; R3, R6, R7 = H, halo, C1-6 alkyl, C1-6 alkoxy] or pharmacol. acceptable salts thereof or prodrug of either are prepared These compds. have excellent human SGLT1 inhibitory activity and are useful as preventives or therapeutic agents for (1) diseases attributable to hyperglycemia such as diabetes, impaired glucose tolerance, complications of diabetes, obesity, hyperinsulinemia, hyperlipidemia, hypercholesteremia, hypertriglycemia, lipid metabolism disorder, atherosclerosis, hypertension, ischemic heart failure, edema, hyperuricemia, or gout and (2) diseases attributable to high level of galactose, galactosemia. For example, 3-(β-D-glucopyranosyloxy)-4-[[4-[3-[2-hydroxy-1,1-bis(hydroxymethyl)ethylcarbamoyl]propyl]phenyl]methyl]-5-isopropyl-1H-pyrazole at 1 mg/kg p.o. lowered blood glucose in diabetic rats from 297±35 to 178±19 mg/dL in 1 h.

IT 661479-73-8P 661479-74-9P 661479-75-0P
661479-76-1P 661479-77-2P 661479-78-3P
661480-16-6P 661480-17-7P 661480-18-8P
661480-19-9P 661480-20-2P 661480-21-3P
661480-22-4P 661480-24-6P 661480-25-7P
661480-26-8P 661480-27-9P 661480-29-1P
661480-32-6P 661480-35-9P 661480-37-1P
661480-39-3P 661480-41-7P 661480-42-8P
661480-43-9P 661480-48-4P 661480-51-9P
661480-53-1P 661480-56-4P 661480-57-5P
661480-58-6P 661480-59-7P 661480-65-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolyl glucopyranoside and galactopyranoside derivs. inhibitors of human sodium-glucose cotransporter 1 (SGLT1) for preventives or therapeutics for diseases related to hyperglycemia or galactosemia)

RN 661479-73-8 CAPLUS

CN Propanamide, N-[(1S)-2-amino-1-methyl-2-oxoethyl]-2,2-dimethyl-3-[4-[[3-(1-methylethyl)-5-[(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)oxy]-1H-pyrazol-4-yl]methyl]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661479-74-9 CAPLUS
CN Propanamide, N-(2-hydroxy-1,1-dimethylethyl)-2,2-dimethyl-3-[4-[[5-(1-methylethyl)-3-[(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)oxy]-1H-pyrazol-4-yl]methyl]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661479-75-0 CAPLUS
CN Propanamide, N-(2-amino-1,1-dimethyl-2-oxoethyl)-2,2-dimethyl-3-[4-[[3-(1-methylethyl)-5-[(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)oxy]-1H-pyrazol-4-yl]methyl]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661479-76-1 CAPLUS

CN Propanamide, N-[(1S)-2-amino-1-methyl-2-oxoethyl]-3-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]phenoxy]-2,2-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661479-77-2 CAPLUS
CN Propanamide, 3-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]phenoxy]-N-(2-hydroxy-1,1-dimethylethyl)-2,2-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661479-78-3 CAPLUS
CN Propanamide, N-(2-amino-1,1-dimethyl-2-oxoethyl)-3-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]phenoxy]-2,2-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661480-16-6 CAPLUS
CN Propanamide, N-(2-amino-1,1-dimethyl-2-oxoethyl)-3-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661480-17-7 CAPLUS
CN Propanamide, 2-[[3-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]phenoxy]-1-oxopropyl]amino]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661480-18-8 CAPLUS

CN Propanamide, 3-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]phenoxy]-N-(2-hydroxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661480-19-9 CAPLUS
CN Propanamide, N-[1,1-dimethyl-2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661480-20-2 CAPLUS
CN Propanamide, N-[1,1-dimethyl-2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3-[4-[[3-(β-D-galactopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661480-21-3 CAPLUS
CN Propanamide, 2-[[3-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]phenoxy]-1-oxopropyl]amino]-N-(2-hydroxyethyl)-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661480-22-4 CAPLUS
CN Propanamide, 3-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]phenoxy]-N-[(1S)-2-hydroxy-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661480-24-6 CAPLUS
CN Propanamide, N-[1,1-dimethyl-2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661480-25-7 CAPLUS
CN Propanamide, 3-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]-N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661480-26-8 CAPLUS
CN Propanamide, 3-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]-N-(2-hydroxy-1,1-dimethylethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661480-27-9 CAPLUS
CN Propanamide, 3-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]-N-[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661480-29-1 CAPLUS
CN Propanamide, 3-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]-N-[2-[4-(2-hydroxyethyl)-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661480-32-6 CAPLUS
CN Propanamide, 2-[[3-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]-1-oxopropyl]amino]-N-(2-hydroxyethyl)-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661480-35-9 CAPLUS
CN Propanamide, 2-[[3-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]-1-oxopropyl]amino]-N-(3-hydroxypropyl)-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661480-37-1 CAPLUS
CN Propanamide, N-[(1S)-2-amino-1-methyl-2-oxoethyl]-3-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661480-39-3 CAPLUS
CN Propanamide, 3-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]-N-[(1S)-3-hydroxy-1-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661480-41-7 CAPLUS

CN Propanamide, N-[(1S)-2-amino-1-(hydroxymethyl)-2-oxoethyl]-3-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661480-42-8 CAPLUS
CN Propanamide, 3-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]-N-[2-hydroxy-1-(hydroxymethyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661480-43-9 CAPLUS
CN Propanamide, 2-[[3-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]-1-oxopropyl]amino]-N-(3-hydroxypropyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661480-48-4 CAPLUS
CN Propanamide, N-[1,1-dimethyl-2-oxo-2-(1-piperazinyl)ethyl]-3-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661480-51-9 CAPLUS
CN Hexanamide, 6-amino-2-[[3-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]-1-oxopropyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661480-53-1 CAPLUS
CN Hexanamide, 2-amino-6-[[3-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]-1-oxopropyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661480-56-4 CAPLUS
CN Butanamide, N-[1,1-dimethyl-2-oxo-2-(1-piperazinyl)ethyl]-4-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



McIntosh

RN 661480-57-5 CAPLUS
CN Butanamide, 4-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]-N-[2-[4-(2-hydroxyethyl)-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661480-58-6 CAPLUS
CN Butanamide, N-[1,1-dimethyl-2-(4-methyl-1-piperazinyl)-2-oxoethyl]-4-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661480-59-7 CAPLUS
CN Butanamide, 4-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]-N-[2-[(2-hydroxyethyl)amino]-1,1-dimethyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661480-65-5 CAPLUS
CN Butanamide, N-[1,1-dimethyl-2-oxo-2-(1-piperazinyl)ethyl]-4-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-[(tetrahydro-2H-pyran-4-yl)oxy]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 661481-25-0P 661481-26-1P 661481-28-3P
661481-29-4P 661481-30-7P 661481-31-8P
661481-35-2P 661481-37-4P 661481-38-5P
661481-39-6P 661481-40-9P 661481-41-0P
661481-60-3P 661481-61-4P 661481-62-5P
661481-63-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolyl glucopyranoside and galactopyranoside derivs. inhibitors of human sodium-glucose cotransporter 1 (SGLT1) for preventives or therapeutics for diseases related to hyperglycemia or galactosemia)
RN 661481-25-0 CAPLUS
CN Alanine, 2-methyl-N-[3-[3-methyl-4-[[3-(1-methylethyl)-5-[(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)oxy]-1H-pyrazol-4-yl]methyl]phenoxy]-1-oxopropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661481-26-1 CAPLUS
CN L-Alanine, N-[3-[3-methyl-4-[[3-(1-methylethyl)-5-[(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)oxy]-1H-pyrazol-4-yl]methyl]phenoxy]-1-oxopropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661481-28-3 CAPLUS
CN Alanine, 2-methyl-N-[4-[3-methyl-4-[[3-(1-methylethyl)-5-[[2,3,4,6-tetrakis-O-(2,2-dimethyl-1-oxopropyl)-β-D-glucopyranosyl]oxy]-1H-pyrazol-4-yl]methyl]phenoxy]-1-oxobutyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661481-29-4 CAPLUS
CN Alanine, 2-methyl-N-[3-[3-methyl-4-[[3-(1-methylethyl)-5-[(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)oxy]-1H-pyrazol-4-yl]methyl]phenoxy]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661481-30-7 CAPLUS
CN L-Alanine, N-[3-[3-methyl-4-[[3-(1-methylethyl)-5-[(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)oxy]-1H-pyrazol-4-yl]methyl]phenoxy]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



McIntosh

RN 661481-31-8 CAPLUS
CN Alanine, 2-methyl-N-[4-[3-methyl-4-[[3-(1-methylethyl)-5-[[2,3,4,6-tetrakis-O-(2,2-dimethyl-1-oxopropyl)-β-D-glucopyranosyl]oxy]-1H-pyrazol-4-yl]methyl]phenoxy]-1-oxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661481-35-2 CAPLUS
CN Propanamide, N-(2-amino-1,1-dimethyl-2-oxoethyl)-3-[3-methyl-4-[[3-(1-methylethyl)-5-[(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)oxy]-1H-pyrazol-4-yl]methyl]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661481-37-4 CAPLUS
CN Propanamide, N-[1,1-dimethyl-2-oxo-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]-3-[3-methyl-4-[[3-(1-methylethyl)-5-[(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)oxy]-1H-pyrazol-4-yl]methyl]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661481-38-5 CAPLUS
CN Propanamide, N-[1,1-dimethyl-2-oxo-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]-3-[4-[[3-(β-D-glucopyranosyloxy)-5-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661481-39-6 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-methyl-2-[[4-[3-methyl-4-[[3-(1-methylethyl)-5-[[2,3,4,6-tetrakis-O-(2,2-dimethyl-1-oxopropyl)-β-D-glucopyranosyl]oxy]-1H-pyrazol-4-yl]methyl]phenoxy]-1-oxobutyl]amino]-1-oxopropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 661481-40-9 CAPLUS
CN Butanamide, N-[1,1-dimethyl-2-oxo-2-(1-piperazinyl)ethyl]-4-[3-methyl-4-[[3-(1-methylethyl)-5-[[2,3,4,6-tetrakis-O-(2,2-dimethyl-1-oxopropyl)-β-D-glucopyranosyl]oxy]-1H-pyrazol-4-yl]methyl]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 661481-41-0 CAPLUS
CN Butanamide, N-[2-[4-(2-hydroxyethyl)-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]-4-[3-methyl-4-[[3-(1-methylethyl)-5-[[2,3,4,6-tetrakis-O-(2,2-dimethyl-1-oxopropyl)-β-D-glucopyranosyl]oxy]-1H-pyrazol-4-yl]methyl]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 661481-60-3 CAPLUS
CN Alanine, 2-methyl-N-[4-[3-methyl-4-[[3-(1-methylethyl)-5-[(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)oxy]-1H-pyrazol-4-yl]methyl]phenoxy]-1-oxobutyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661481-61-4 CAPLUS
CN Alanine, 2-methyl-N-[4-[4-[[3-(1-methylethyl)-5-[[2,3,4,6-tetrakis-O-(2,2-dimethyl-1-oxopropyl)-β-D-glucopyranosyl]oxy]-1H-pyrazol-4-yl]methyl]-3-[(tetrahydro-2H-pyran-4-yl)oxy]phenoxy]-1-oxobutyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661481-62-5 CAPLUS
CN Alanine, 2-methyl-N-[4-[3-methyl-4-[[3-(1-methylethyl)-5-[(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)oxy]-1H-pyrazol-4-yl]methyl]phenoxy]-1-oxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661481-63-6 CAPLUS
CN Alanine, 2-methyl-N-[4-[4-[[3-(1-methylethyl)-5-[[2,3,4,6-tetrakis-O-(2,2-dimethyl-1-oxopropyl)-β-D-glucopyranosyl]oxy]-1H-pyrazol-4-yl]methyl]-3-[(tetrahydro-2H-pyran-4-yl)oxy]phenoxy]-1-oxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:950052 CAPLUS
DN 140:13040
TI Combined use of TACE inhibitors and COX2 inhibitors as anti-inflammatory agents
IN Duan, Jingwu
PA USA
SO U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003225054	A1	20031204	US 2003-453036	20030603
PRAI	US 2002-385656P	P	20020603		

OS MARPAT 140:13040
AB This invention relates to a method of treating inflammatory diseases in a mammal comprising administering to the mammal a therapeutically effective amount of a combination of: (i) at least one TACE inhibitor, (ii) one or more anti-inflammatory agents selected from the group consisting of: selective COX-2 inhibitors, interleukin-1 antagonists, dihydroorotate synthase inhibitors, p38 MAP kinase inhibitors, TNF-α inhibitors, TNF-α sequestration agents, and methotrexate. The invention also relates to compns. and kits containing the same.
IT 461664-87-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combined use of TACE inhibitors and COX2 inhibitors as anti-inflammatory agents)
RN 461664-87-9 CAPLUS
CN 1-Oxaspiro[4.4]nonane-7-carboxamide, 8-[[4-[(3,5-dimethyl-1H-pyrazol-4-yl)methyl]benzoyl]amino]-N-hydroxy-, (5R,7S,8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:551497 CAPLUS
DN 139:117419
TI Preparation of 1-(aminoethyl)-substituted-1H-pyrazoles for use in diseases associated with the 5-HT2c receptor
IN Ladouceur, Gaetan H.; Velthuisen, Emil; Choi, Soongyou; Wang, Yamin; Baryza, Jeremy L.; Coish, Phillip; Bullock, William; Smith, Roger; Chen, Michael
PA Bayer Corporation, USA
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003057673	A1	20030717	WO 2002-US41634	20021228
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2471880	A1	20030717	CA 2002-2471880	20021228
	AU 2002360818	A1	20030724	AU 2002-360818	20021228
	EP 1465871	A1	20041013	EP 2002-796100	20021228
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	US 2005119246	A1	20050602	US 2003-499786	20021228
	JP 2005516964	T	20050609	JP 2003-557990	20021228
PRAI	US 2001-344149P	P	20011228		
	WO 2002-US41634	W	20021228		

OS MARPAT 139:117419
GI



I



II

AB Title compds. I [R = H, alk(en/yn)yl, aryl, etc.; R1-2 = H, alk(en/yn)yl; R5-6 = H, alkyl] are prepared For instance, 4-bromo-3,5-dimethylpyrazole is coupled to phenylboronic acid (PhMe, PdCl2(PPh3)2, Na2CO3, 90°, 18 h) and alkylated with 2-chloroethylamine•HCl (CH3CN, NaOH) to give II. Example compds. have an effect on the 5-HT2c receptor at ≤ 10

McIntosh

μM. I are useful for the treatment of obesity.

IT 562816-63-1P 562816-64-2P 562816-65-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-(aminoethyl)-substituted-1H-pyrazoles for use in diseases associated with the 5-HT2c receptor)

RN 562816-63-1 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, N-[4-[[1-[(2S)-2-aminopropyl]-3,5-diethyl-1H-pyrazol-4-yl]methyl]benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 562816-64-2 CAPLUS
CN Benzamide, 4-[[1-[(2S)-2-aminopropyl]-3,5-diethyl-1H-pyrazol-4-yl]methyl]-N-(2,2-dimethyl-1-oxopropyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 562816-65-3 CAPLUS
CN Benzamide, 4-[[1-[(2S)-2-aminopropyl]-3,5-diethyl-1H-pyrazol-4-yl]methyl]-N-(cyclopropylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:242160 CAPLUS
DN 138:271705
TI Preparation of triazinyl and other carboxamides as inhibitors of histone deacetylase
IN Delorme, Daniel; Woo, Soon Hyung; Vaisburg, Arkadii; Moradel, Oscar; Leit, Silvana; Raeppel, Stephane; Frechette, Sylvie; Bouchain, Giliane
PA Methylgene, Inc., Can.
SO PCT Int. Appl., 347 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003024448	A2	20030327	WO 2002-US29017	20020912
	WO 2003024448	A3	20031113		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2465978	A1	20030327	CA 2002-2465978	20020912
	EP 1429765	A2	20040623	EP 2002-763627	20020912
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002012510	A	20040824	BR 2002-12510	20020912
	CN 1578663	A	20050209	CN 2002-822690	20020912
	JP 2005508905	T	20050407	JP 2003-528544	20020912
	JP 3795044	B2	20060712		
	IN 2004KN00257	A	20061110	IN 2004-KN257	20040225
	JP 2005255683	A	20050922	JP 2005-80310	20050318
	AU 2006252047	A1	20070111	AU 2006-252047	20061214
PRAI	US 2001-322402P	P	20010914		
	US 2002-391728P	P	20020626		
	AU 2002-327627	A3	20020912		
	JP 2003-528544	A3	20020912		
	WO 2002-US29017	W	20020912		

OS MARPAT 138:271705
GI



I

AB The invention relates to triazines (shown as I; variables defined below; e.g. 4-[[4-amino-6-(2-indanylamino)-[1,3,5]triazin-2-ylamino]methyl]-N-(2-aminophenyl)benzamide) and Cy3-X1-Ar2-(C(R5):C(R6))qC(O)NH-Ay2 (II; variables defined below; e.g.), many of which are N-(o-aminophenyl)carboxamides, as inhibitors of histone deacetylase (data included for many I and II). The invention provides compds. and methods for inhibiting histone deacetylase enzymic activity. The invention also provides compns. and methods for treating cell proliferative diseases and conditions. Antineoplastic effects of some I and II are illustrated for colorectal, pulmonary and pancreatic neoplasms; also the combined antineoplastic effect of histone deacetylase inhibitors and histone deacetylase antisense oligonucleotides on tumor cells in vivo was demonstrated. For I: R3 and R4 = H, L1, Cy1 and -L1-Cy1 (L1 = C1-C6 alkyl, C2-C6 heteroalkyl, or C3-C6 alkenyl; Cy1 = cycloalkyl, aryl, heteroaryl, or heterocyclyl) or R3 and R4 are taken together with the adjacent N atom to form a 5-, 6-, or 7-membered ring, wherein the ring atoms = C, O, S, and N, and wherein the ring is optionally substituted, and optionally forms part of a bicyclic ring system, or is optionally fused to one or two aryl or heteroaryl rings, or to one or two saturated or partially unsatd. cycloalkyl or heterocyclic rings, each of which rings and ring systems is optionally substituted. Y1 = -N(R1)(R2), -CH2-C(O)-N(R1)(R2), halogen, and H (R1 and R2 = H, L1, Cy1, and -L1-Cy1). Y2 = chemical bond or N(R0) (R0 = H, alkyl, aryl, aralkyl, and acyl); Ak1 = C1-C6 alkylene, C1-C6-heteroalkylene (preferably, in which one -CH2- is replaced with -NH-, and more preferably -NH-CH2), C2-C6 alkenylene or C2-C6 alkynylene; Ar1 = arylene or heteroarylene, either of which is optionally substituted; and Z1 = C(O)NH-Ay1 and CH:CHC(O)NH-Ay1 (Ay1 = aryl or heteroaryl, each of which is optionally substituted). For II: Cy2 = cycloalkyl, aryl, heteroaryl, or heterocyclyl; X1 = covalent bond, M1-L2-M1, and L2-M2-L2 (L2 = chemical bond, C1-C4 alkylene, C2-C4 alkenylene, and C2-C4 alkynylene, provided that L2 is not a chemical bond when X1 is M1-L2-M1; M1 = -O-, -N(R7)-, -S-, -S(O)-, S(O)2-, -S(O)2N(R7)-, -N(R7)S(O)2-, -C(O)-, -C(O)NH-, -NHC(O)-, -NHC(O)-O- and -OC(O)NH- (R7 = H, alkyl, aryl, aralkyl, acyl, heterocyclyl, and heteroaryl); and M2 = M1, heteroarylene, and heterocyclylene, either of which rings is optionally substituted). Ar2 = arylene or heteroarylene, each of which is optionally substituted; R5 and R6 = H, alkyl, aryl, and aralkyl; q is 0 or 1; and Ay2 is a 5-6 membered cycloalkyl, heterocyclyl, or heteroaryl substituted with an amino or hydroxy moiety (preferably these groups are ortho to the amide N to which Ay2 is attached) and further optionally substituted; provided that when Cy2 is naphthyl, X1 is -CH2-, Ar2 is Ph, R5 and R6 are H, and q is 0 or 1, Ay2 is not Ph or o-hydroxyphenyl. Although the methods of preparation are not claimed, hundreds of example prepns. are included.

IT 503040-37-7P, N-(2-Aminophenyl)-4-[(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)methyl]benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of triazinyl and other carboxamides as inhibitors of histone deacetylase for treating cell proliferative disorders)

RN 503040-37-7 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-[(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:927249 CAPLUS
DN 138:14059
TI Preparation of spiro-fused hydantoin derivatives as inhibitors of matrix metalloproteinases
IN Sheppeck, James E.; Duan, Jingwu; Xue, Chu-Biao; Wasserman, Zelda
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 350 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002096426	A1	20021205	WO 2002-US16381	20020523
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2447475	A1	20021205	CA 2002-2447475	20020523
	US 2003130273	A1	20030710	US 2002-155575	20020523
	US 6890915	B2	20050510		
	EP 1397137	A1	20040317	EP 2002-741724	20020523
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004535411	T	20041125	JP 2002-592936	20020523
	US 2004209874	A1	20041021	US 2004-844219	20040512
	US 6906053	B2	20050614		
	US 2005171096	A1	20050804	US 2005-93670	20050330
PRAI	US 2001-293571P	P	20010525		
	US 2002-155575	A3	20020523		
	WO 2002-US16381	W	20020523		
	US 2004-844219	A3	20040512		

OS MARPAT 138:14059
GI



I



II

AB Title compds. I [R11 = W-U-X-Y-Z-Ua-Xa-Ya-Za; W = alkyl, alkenylene, alkynylene; U = absent, amino, CO, alkyl, carboxy, etc.; X = absent, alk(en/yn)ylene; Y = absent, O, amino, SOO-2, CO; Z = (hetero)cycle; Ua = absent, O, amino, CO, alkyl, carboxy, etc.; Xa = absent, alk(en/yn)ylene; Ya = absent, O, amino, SOO-2, CO; Za = (hetero)cycle; R1-2 together with the carbon atoms to which they are attached, combine to form a 3-8 membered carbocyclic or heterocyclic ring; R3 = H, CHF2, CH2F, CF3, alk(en/yn)ylene, etc.; R4-7 = H, alk(en/yn)yl; n = 0-1] were prepared For instance, 2-(ethylcarboxy)cyclohexanone was treated with ammonium carbonate and potassium cyanide (EtOHaq, 50°, 24 h) to afford the corresponding hydantoin ester which was hydrolyzed to the carboxylic acid and coupled to 4-[(2-methyl-4-quinolinyl)methoxy]aniline•2HCl (DMSO, PyBOP) to give II which was isolated as the trifluoroacetate. I are useful as inhibitors of matrix metallproteinases (MMP), TNF-α converting enzyme (TACE), aggrecanase, or a combination thereof.

IT 477582-04-0P 477582-08-4P, N-(2,4-Dioxo-7-oxa-1,3-diazaspiro[4.5]dec-10-yl)-4-[(1,3,5-trimethyl-1H-pyrazol-4-yl)methyl]benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(hydantion derivs. as inhibitors of matrix metalloproteinases)

RN 477582-04-0 CAPLUS

CN Benzamide, 4-[(3,5-dimethyl-1H-pyrazol-4-yl)methyl]-N-(2,4-dioxo-7-oxa-1,3-diazaspiro[4.5]dec-10-yl)- (9CI) (CA INDEX NAME)



RN 477582-08-4 CAPLUS

CN Benzamide, N-(2,4-dioxo-7-oxa-1,3-diazaspiro[4.5]dec-10-yl)-4-[(1,3,5-

trimethyl-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:736225 CAPLUS
DN 137:262960
TI Preparation of spiro-cyclic β-amino acid derivatives as inhibitors of matrix metalloproteinases and TNF-α converting enzyme (TACE)
IN Ott, Gregory R.; Chen, Xiaotao; Duan, Jingwu; Voss, Matthew E.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 187 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002074738	A2	20020926	WO 2002-US7652	20020312
	WO 2002074738	A3	20030403		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2439539	A1	20020926	CA 2002-2439539	20020312
	US 2003087882	A1	20030508	US 2002-96804	20020312
	US 6720329	B2	20040413		
	EP 1373199	A2	20040102	EP 2002-728458	20020312
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2004132693	A1	20040708	US 2003-741326	20031218
	US 6962938	B2	20051108		
PRAI	US 2001-275898P	P	20010315		
	US 2002-96804	A3	20020312		
	WO 2002-US7652	W	20020312		

OS MARPAT 137:262960
AB Novel spiro-cyclic β-amino acid derivs. C-B-NR1CO-Z-Ua-Xa-Ya-Za [C-B represents a spiro-cyclic ring system, where rings B and C are 3-13 membered carbocycles or heterocycles; ring B is bonded to NR1 via ACR2aCR2b-; A = alkanoyl, CO2H or ester, CH2CO2H, CONHOH, SH, CH2SH, etc.; R2a = H, alkyl, OH, alkoxy, an amino group, S(O)p (p = 0-2), etc.; R2b = H, alkyl; R1 = H, alkyl, Ph, PhCH2; Z is absent or is a carbocycle or heterocycle; Ua is absent or is O, NH, alkylimino, CO, CO2, O2C, CONH,

S(O)p, etc.; Xa is absent or is alkylene, alkenylene, or alkynylene; Ya is absent or is O, NH, alkylimino, S(O)p, CO; Za = H, carbocycle, or heterocycle] or their pharmaceutically-acceptable salts were prepared as matrix metalloproteinases (MMP), TNF-α converting enzyme (TACE), and/or aggrecanase inhibitors. Thus, (7S,8R)-N-hydroxy-8-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1,4-dioxaspiro[4.4]nonane-7-carboxamide was prepared by a multistep synthesis starting from (1S,2R)-1-Me cis-1,2,3,6-tetrahydrophthalate. The latter underwent sequential esterification with benzyl alc., oxidative ring opening with KMnO4, and recyclization with Ac2O/NaOAc to yield intermediate benzyl Me (1S,2R)-4-oxo-1,2-cyclopentanedicarboxylate.

IT 461664-87-9P 461664-88-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of spiro-cyclic β-amino acid derivs. as inhibitors of matrix metalloproteinases and TNF-α converting enzyme (TACE))

RN 461664-87-9 CAPLUS
CN 1-Oxaspiro[4.4]nonane-7-carboxamide, 8-[[4-[(3,5-dimethyl-1H-pyrazol-4-yl)methyl]benzoyl]amino]-N-hydroxy-, (5R,7S,8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 461664-88-0 CAPLUS
CN 1-Oxaspiro[4.4]nonane-7-carboxamide, N-hydroxy-8-[[4-[(1,3,5-trimethyl-1H-pyrazol-4-yl)methyl]benzoyl]amino]-, (5R,7S,8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 461665-66-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of spiro-cyclic β-amino acid derivs. as inhibitors of matrix metalloproteinases and TNF-α converting enzyme (TACE))

RN 461665-66-7 CAPLUS
CN 1-Oxaspiro[4.4]nonane-7-carboxylic acid, 8-[[4-[(3,5-dimethyl-1H-pyrazol-4-yl)methyl]benzoyl]amino]-, methyl ester, (5R,7S,8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:171866 CAPLUS
DN 136:232313
TI Preparation of pyrimidine derivatives as G protein-coupled receptor kinase (GRK) inhibitors
IN Fukumoto, Shoji; Watanabe, Toshifumi; Ikeda, Shota
PA Takeda Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 322 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002018350	A1	20020307	WO 2001-JP7397	20010829
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001082520	A5	20020313	AU 2001-82520	20010829
	JP 2002145778	A	20020522	JP 2001-259683	20010829
PRAI	JP 2000-264499	A	20000829		
	WO 2001-JP7397	W	20010829		

OS MARPAT 136:232313
GI



I

AB Disclosed are novel GRK inhibitors which contains compds. represented by the formula (I), a salt thereof, or a prodrug comprising either of these (wherein ring A represents optionally further substituted nitrogen-containing heterocycle; R1 and R2 each represents optionally substituted amino; and X represents a spacer comprising a linear part constituted of one to four atoms, provided that R1 may be bonded to R2 or/and X to form a ring). They are useful as preventives/remedies for cardiac failure. Thus, 5.48 g K2CO3 and 7.52 g 2-aminophenyl 2-nitrophenyl sulfide were added to a suspension of 5.61 g 4-amino-5-bromomethyl-2-methylpyrimidine hydrobromide in 40 mL acetone at room temperature and stirred at 65° for 64 h to give 2.36 g N-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-N-[2-[(2-nitrophenyl)thio]phenyl]amine (II). All 10 compds. tested including II at 30 μM inhibited 30% human GRK2 expressed by human GRK2 gene in COS-7 cells. A capsule and a tablet formulation containing II were also prepared

IT 403515-13-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(preparation of pyrimidine derivs. as G protein-coupled receptor kinase (GRK) inhibitors for prevention and/or treatment for cardiac failure)

RN 403515-13-9 CAPLUS

CN Benzamide, N-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-4-[(3,5-diphenyl-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 13:42:38 ON 01 APR 2007)

FILE 'REGISTRY' ENTERED AT 13:43:00 ON 01 APR 2007
L1 STRUCTURE UPLOADED
L2 5 S L1 SSS SAM
L3 72 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 13:43:48 ON 01 APR 2007
L4 12 S L3